Please login to the form below

Not currently logged in
Email:
Password:

antisense drugs

This page shows the latest antisense drugs news and features for those working in and with pharma, biotech and healthcare.

Janssen partners with Isis on stomach conditions

Janssen partners with Isis on stomach conditions

The two companies will focus on developing so-called'antisense' drugs that bind to the genetic sequence of a faulty gene in order to treat autoimmune disorders that affect the gastrointestinal ... Kynamro, which was approved by the US FDA at the

Latest news

  • Biogen Idec gets exclusive access to Isis' neurology R&D Biogen Idec gets exclusive access to Isis' neurology R&D

    Biogen Idec gets exclusive access to Isis' neurology R&D. Fourth deal in two years with antisense specialist. ... of up to $220m for antisense drugs developed under the collaboration plus royalties on any eventual sales.

  • Roche and Isis in $392m deal to research drugs for brain disorder Roche and Isis in $392m deal to research drugs for brain disorder

    Will develop antisense drugs for Huntington's disease. Roche is to partner with Isis Pharmaceuticals to research medicines for the Huntington's disease – a rare, genetic brain disorder for which there ... To complement this research, Roche will combine

  • Biogen Idec licenses antisense drugs from Isis in $630m deal Biogen Idec licenses antisense drugs from Isis in $630m deal

    Biogen Idec licenses antisense drugs from Isis in $630m deal. Gains neurological and neuromuscular disorder projects. ... Biogen Idec has signed its third licensing agreement with antisense specialist Isis Therapeutics in less than a year, paying $30m

  • Genentech signs $646m pain drug research alliance with Xenon

    Xenon has a deal with Japanese company Takeda Pharamceuticals to develop treatments for pain and collaborations with Novartis for obesity treatments, Merck &Co for cardiovascular drugs and Isis Pharmaceuticals for antisense

  • RNA interference rebirth RNA interference rebirth

    The rationale for targeting RNA is compelling. It is estimated that existing small-molecule and biologic drugs can only address around a fifth of the genes in the human genome, but ... Finally another company, Santaris, is using both a traditional

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Pharma deals in August 2015 Pharma deals in August 2015

    510. Isis. Antisense drugs for CVS metabolic and renaldisease. 65. Mirati Therapeutics. ... Exclusive licence. 90. Isis. AZ. Addition to Dec 2012 collaboration to develop antisense drugs in oncology.

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Strategic collaboration. 1, 000. Isis/ Janssen. Antisense drugs to treat autoimmune disorders of the GI tract - local and oral therapies (3 programmes).

  • Pharma deals during January 2015 Pharma deals during January 2015

    A $35m payment went in an upfront to Isis as part of its $835m headline deal for a collaboration to discover and develop antisense drugs in autoimmune disorders in the GI ... tract. The deal includes options to license drugs arising from the various

  • Pharma deals during December 2012 Pharma deals during December 2012

    an upfront of $30m, to discover and co-develop antisense drugs to treat three neurological or neuromuscular disorders. ... 231. Isis / Biogen. Co-development and option to licence. Discovery / research of antisense drugs.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashley Communications

Ashley Communications is a bespoke, independent medical communications consultancy consistently providing a unique director-delivered client service tailored to individual client...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics